Abstract: A system and method for MRI are provided. a plurality of RF parameters for an MRI scan, using an MRI scanner, of a subject may be obtained. A first power loss and a first current square factor of the RF coil assembly under an unloaded condition of the MRI scanner may be determined based on the plurality of RF parameters. A total power loss of the MRI scan and a second current square factor of the RF coil assembly during the MRI scan may be determined based on the plurality of RF parameters. A second power loss of the RF coil assembly during the MRI scan may be determined based on the first power loss, the first current square factor, and the second current square factor. A SAR of the subject during the MRI scan may be determined based on the total power loss and the second power loss.

Abstract: A transceiver circuit having a T-coil circuit, inductive termination, and an equalization circuit is disclosed. The transceiver includes a transmitter having an output coupled to a first node, and a receiver having an input coupled to the first node. A T-coil circuit is coupled between the first node and an input/output (I/O) node. The T-coil circuit includes first and second inductors coupled in series between the first node and the I/O node, the inductors being coupled at a second node. A termination circuit is coupled between the first node and a reference node, the termination circuit including a third inductor. The transceiver circuit also includes an equalization circuit configured to convey an equalization signal to the second node.

Abstract: The present invention provides compositions and methods for the detection, treatment, and prevention of emphysema/COPD. Compositions of the present invention comprise TLR4 activators, Nox3 inhibitors, and Cathepsin E inhibitors useful in the treatment or prevention of emphysema/COPD. Cathepsin E is a downstream effector of TLR4, wherein when cathepsin E is overexpressed in lung of an individual, the individual is at higher risk of developing emphysema/COPD. Cathepsin E is further identified as a biomarker useful in the identification of an individual with, or at-risk of developing emphysema/COPD.

Abstract: Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.

Abstract: Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA. Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.